TNF and Cowden disease: However, the LOR in some patients could possibly be due to a less anti-TNF driven pathway of inflammation (31), as suggested by the good response rates in the recent ustekinumab trial, a monoclonal antibody directly targeted against interleukin (IL)-12 and IL-23, in TNF-refractory CD patients (32,33).